287 related articles for article (PubMed ID: 16115932)
1. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
[TBL] [Abstract][Full Text] [Related]
2. Personalized, multivalent, and more affordable: the globalization of vaccines.
Debinski W
Clin Cancer Res; 2005 Aug; 11(16):5663-4. PubMed ID: 16115899
[No Abstract] [Full Text] [Related]
3. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
4. Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
Yamamoto K; Mine T; Katagiri K; Suzuki N; Kawaoka T; Ueno T; Matsueda S; Yamada A; Itoh K; Yamana H; Oka M
Oncol Rep; 2005 May; 13(5):874-83. PubMed ID: 15809753
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
[TBL] [Abstract][Full Text] [Related]
7. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
Clin Cancer Res; 2001 Dec; 7(12):3950-62. PubMed ID: 11751487
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
[TBL] [Abstract][Full Text] [Related]
9. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC; Harlin H; Gajewski TF
J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
[TBL] [Abstract][Full Text] [Related]
13. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
14. Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancy.
Takedatsu H; Yoshimoto K; Okamura T; Yakushij K; Imamura R; Hashiguchi M; Seki R; Obata Y; Harada M; Yamada A; Yamana H; Sata M; Itoh K
Int J Oncol; 2005 Jun; 26(6):1605-12. PubMed ID: 15870876
[TBL] [Abstract][Full Text] [Related]
15. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
Harada M; Ishihara Y; Itoh K; Yamanaka R
Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
Noguchi M; Itoh K; Yao A; Mine T; Yamada A; Obata Y; Furuta M; Harada M; Suekane S; Matsuoka K
Prostate; 2005 Apr; 63(1):1-12. PubMed ID: 15378520
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
Yutani S; Yamada A; Yoshida K; Takao Y; Tamura M; Komatsu N; Ide T; Tanaka M; Sata M; Itoh K
Vaccine; 2007 Oct; 25(42):7429-35. PubMed ID: 17845828
[TBL] [Abstract][Full Text] [Related]
19. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
20. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]